VacPertagen (pertussis vaccine (recombinant, acellular, component, adsorbed))
- Region
- 🇪🇺 EU
- Active substance
- pertussis vaccine (recombinant, acellular, component, adsorbed)
- Company
- BioNet Europe
- Status
- Authorised
- Therapeutic area
- Whooping Cough; Infections
- CHMP opinion
- Thu 13 Nov 2025
- EU approval
- Fri 09 Jan 2026
- Application
- EMEA/H/C/006304
- ATC
- J07AJ02
- Official record
- www.ema.europa.eu
Indication
VacPertagen is indicated for: - booster immunisation against pertussis of individuals 12 years of age and older,- passive protection against pertussis in early infancy following maternal immunisation during pregnancy.
Regulatory milestones
Fri 09 Jan 2026🇪🇺 EU approval (EC decision)
VacPertagen (pertussis vaccine (recombinant, acellular, component, adsorbed)) approved in the EU
Marketing authorisation to BioNet Europe · source
Thu 13 Nov 2025🇪🇺 CHMP positive opinion
VacPertagen (pertussis vaccine (recombinant, acellular, component, adsorbed)): CHMP positive opinion
Follow VacPertagen
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.